Schedule of SYSUCC Presenters

Find out when SYSUCC experts are presenting during the ASCO meeting.

Learn more

A total of 13 studies from Sun Yat-sen University Cancer Center are selected as oral presentations by ASCO, and the latest research results in the treatment strategies of various cancer types will be presented at the ASCO meeting this year.

1. Rui-Hua Xu, MD, PhD
Department of Medical Oncology, Sun Yat-sen University Cancer Center
Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study
Abstract：3505


2. Xu Liu,MD, PhD
Department of Radiation Oncology, Sun Yat-sen University Cancer Center
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
Abstract：LBA6000


3. Qiu-Yan Chen,MD, PhD
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.
Abstract：6001


4. Li Zhang,MD, PhD
Department of Medical Oncology, Sun Yat-sen University Cancer Center
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial
Abstract：8508


5. Wenfeng Fang, MD, PhD
Department of Medical Oncology, Sun Yat-sen University Cancer Center
Sacituzumab tirumotecan in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study
Abstract：8502

6. Si-Yu Wang,MD, PhD

Department of Thoracic Surgery, Sun Yat-sen University Cancer Center
Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial
Abstract：8004

7. Hui Liu  MD, PhD
Department of Radiation Oncology, Sun Yat sen University Cancer Center
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091)
Abstract：8008

8. Haibo Qiu, MD, PhD
Department of Gastric Surgery, Sun Yat-sen University Cancer Center
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. 
Abstract：11502

9. Jihong Liu, MD, PhD
Department of Gynecologic Oncology, Sun Yet Sen University Cancer Center
Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial
Abstract：5512

10. Dan-yun Ruan,MD, PhD

Department of Clinical Research, Sun Yat-sen University Cancer Center
Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors）. 
Abstract：6013

11. Ming Song,MD, PhD

Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center
Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial
Abstract：6011

Abstract：438730

Written by: Liao Shuang, Zhai Huiwen

                                                                                                            International Office, 

Sun Yat-sen University Cancer Center